A 53-year-old with obesity and type 2 diabetes is on metformin and SGLT2 inhibitor; A1c 7.4%. eGFR 72. To enhance weight loss and glycaemic control, w...

Question

A 53-year-old with obesity and type 2 diabetes is on metformin and SGLT2 inhibitor; A1c 7.4%. eGFR 72. To enhance weight loss and glycaemic control, which addition has proven CV benefit?

Accepted Answer

GLP-1 receptor agonist

Answer

DPP-4 inhibitor

Answer

Sulfonylurea

Answer

Basal insulin

Answer

Alpha-glucosidase inhibitor

us-usmle-step-2 MCQ (SBA): Diabetes Combination Therapy

A 53-year-old with obesity and type 2 diabetes is on metformin and SGLT2 inhibitor; A1c 7.4%. eGFR 72. To enhance weight loss and glycaemic control, which addition has proven CV benefit?